ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1361	National Cancer Institute	Html	en	Esophageal Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of esophageal cancer.	esophageal mucosa 0.388276 Surg Gynecol Obstet 0.322065 upper thoracic esophagus 0.424827 Engl J Med 0.487637 oesophageal cancer 0.359132 esophagus extends 0.400639 Gastrointest Endosc 0.369631 preoperative chemotherapy 0.369817 Ann Surg Oncol 0.343391 Radiation Therapy Oncology 0.363113 lower esophagus 0.428306 randomized trial 0.366127 patients 0.358564 thermal ablation therapy 0.326198 Coll Surg 0.323431 esophageal obstruction 0.464185 cervical esophagus 0.414894 esophageal adenocarcinoma 0.376246 endoscopic laser therapy 0.333059 radiation therapy 0.485551 partial esophageal obstruction 0.426095 esophageal carcinoma 0.425086 Malignant esophageal obstruction 0.414655 et al. 0.60539 esophageal cancers results 0.439813	surgery versus surgery 0.374104 esophageal cancer 0.911438 multicenter randomized trial 0.34111 Therapy Oncology Group 0.366143 PUBMED Abstract 0.490901 Surgical treatment 0.372648 advanced esophageal cancer 0.428676 locoregional esophageal carcinoma 0.419242 Thorac Cardiovasc Surg 0.334758 Semin Surg Oncol 0.357463 definitive radiation therapy 0.326973 complete esophageal obstruction 0.428536 Abstract 0.52332 Clin Oncol 0.7331 Council Oesophageal Cancer 0.337988 inoperable malignant dysphagia 0.325697 junctional cancer 0.327281 Minimally invasive surgery 0.326119 van Sandick JW 0.37682 van Lanschot JJ 0.562871 chemoradiation versus surgery 0.346134 esophagus 0.550763 phase III trial 0.333959 squamous cell carcinoma 0.57882	CLICK HERE
1684	National Cancer Institute	Html	en	Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Gastrointestinal Stromal Tumors	imatinib response 0.41821 higher-dose imatinib mesylate 0.47787 imatinib therapy. 0.433313 Demetri GD 0.381845 TKI imatinib mesylate 0.494206 KIT receptor tyrosine 0.378346 KIT exon 0.370015 gastrointestinal stromal cell 0.41709 KIT-expressing primary GIST 0.416866 small GIST tumors 0.5328 gastrointestinal stromal tumour 0.414558 patients 0.452898 primary GIST 0.421404 complete gross resection 0.401005 adjuvant imatinib 0.525629 gastrointestinal stromal tumor 0.540132 GIST morphology 0.406777 high-dose imatinib 0.421288 stromal tumor resection 0.405207 tyrosine kinase inhibitor 0.379801 GIST patients 0.413735 et al. 0.374864 GIST resection 0.432449 tyrosine kinase 0.423999	metastatic GIST 0.418294 imatinib resistance 0.431916 gastrointestinal stromal tumors 0.903165 recurrent GIST 0.424604 imatinib mesylate 0.752767 imatinib therapy 0.416737 tyrosine kinase inhibitors 0.389426 imatinib ultimately experience 0.466343 GIST range 0.411206 imatinib-resistant GIST 0.405402 GIST 0.738771 Abstract 0.430607 common mesenchymal tumors 0.369545 Clin Oncol 0.46383 imatinib doses 0.430101 imatinib arm 0.426642 Familial GIST 0.424119 indolent GIST 0.42682 gastrointestinal stromal tumours 0.756245 imatinib era 0.421816 inoperable GIST 0.404394 new GIST cases 0.474154 advanced incurable GIST 0.424115 postoperative adjuvant imatinib 0.452036	CLICK HERE
1691	National Cancer Institute	Html	en	Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)–Health Professional Version	Calcium, green tea, lycopene, pomegranate, selenium, soy and vitamin E have been studied for prostate cancer prevention or treatment. Read about laboratory and human studies on various prostate supplements in this expert-reviewed summary.	atypical small acinar 0.591788 dietary lycopene 0.5816 local-stage prostate cancer 0.605358 prostate cancer cell 0.611618 prostate cancer survivors 0.597981 total prostate cancer 0.586726 occult prostate cancer 0.591218 lycopene serum concentration 0.581941 lycopene intake 0.604495 prostate cancer cells. 0.594787 serum lycopene 0.591044 hormone-refractory prostate cancer 0.585389 metastatic prostate cancer 0.596215 cancer prostate cells 0.587339 prostate cancer incidence 0.586787 prostate cancer cells 0.74273 prostate cancer risk 0.675977 prostate cancer patients 0.695715 serum lycopene concentrations 0.582255 prostate cancer aggressiveness 0.585035 prostate cancer progressi 0.584763 lycopene 0.683385 end-of-study prostate lycopene 0.623399 Prostate Cancer Prevention 0.597202 serum psa levels 0.589012	human prostate cancer 0.61272 plasma lycopene levels 0.594142 study 0.645275 androgen-independent prostate cancer 0.585034 prostate cancer development 0.59941 nonmetastatic prostate cancer 0.584711 -resistant prostate cancer 0.587482 high-grade prostate cancer 0.596056 Prostate CAncer Therapy 0.605352 prostate cancer mortality 0.5969 prostate cancer biomarkers 0.590502 prostate cancer cases 0.586568 prostate lycopene concentration 0.627986 green tea 0.644093 prostate cancer patients. 0.585445 lycopene blood levels 0.586499 prostate cancer 0.954937 prostate cancer. 0.620441 aggressive prostate cancer 0.587452 prostate cancer risk. 0.60813 prostate cancer progression 0.591862 prostate lycopene concentrations 0.629097 lycopene levels 0.595352 small acinar proliferation 0.592927	CLICK HERE
1906	National Cancer Institute	Html	es	Tratamiento de la leucemia linfocítica crónica (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfocítica crónica.	origen judío ruso 0.422021 siguientes procedimientos 0.424569 células madre 0.989491 estadio iv 0.439551 siguientes aspectos 0.415966 proteína llamada bcl2 0.417559 leucemia linfoblástica aguda 0.524325 hueso compacto 0.45509 neoplasias mieloides 0.413049 rayos x 0.41087 Chronic Lymphocytic Leukemia 0.453986 estadios i 0.422864 enlace drugs approved 0.452281 célula madre mieloide 0.477075 células mieloides 0.465027 células t 0.445647 células anormales.ampliar aspiración 0.467907 National Cancer Institute 0.4112 sexo masculino 0.412514 Instituto Nacional 0.418791	LLC mejora 0.413093 célula madre linfoide 0.435741 PDQ Tratamiento 0.432911 exploración tep 0.412807 siguientes problemas 0.415002 presente sección 0.408632 leucemia mielógena 0.445228 explorador tep 0.413444 tirosina cinasa 0.45926 Physician Data Query 0.439508 estadio iii 0.439039 linfocitos t 0.431485 laboratorio piezas 0.414056 Antecedentes familiares 0.410684 leucemia mieloide aguda 0.50943 célula madre 0.588281 células sanguíneas maduras 0.551856 gen igvh 0.469992 siguientes sumarios 0.426268 siguientes pruebas 0.415779	CLICK HERE
1910	National Cancer Institute	Html	es	Tratamiento de los tumores carcinoides gastrointestinales (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores carcinoides gastrointestinales.	tejido tumoral carcinoide 0.303641 electrodos minúsculos 0.300961 tumor carcinoide 0.379006 siguientes procedimientos 0.32226 pequeña cámara 0.300969 pequeña cantidad 0.300995 claro cuál 0.301673 rayos x 0.301155 tumores carcinoides gi 0.541315 cromogranina a 0.301286 ondas sonoras 0.301178 síndrome carcinoide 0.405552 pequeño efecto 0.300747 tumores neuroendocrinos 0.31718 National Cancer Institute 0.300501 tumores carcinoide gi 0.305034	siguientes riesgos 0.300555 endocrina múltiple tipo 0.30275 Instituto Nacional 0.300956 PDQ Tratamiento 0.301284 neurofibromatosis tipo 0.301611 tubo gi 0.311684 Physician Data Query 0.302032 pimientos chili 0.300797 carcinoides gi recidivantes 0.302839 Antecedentes familiares 0.301159 cuerpo cantidades 0.303122 hígado ayuda 0.301344 tumores carcinoides 0.989957 tumor carcinoide gi 0.311705 siguientes sumarios 0.303432 células neuroendocrinas 0.30282	CLICK HERE
1928	National Cancer Institute	Html	es	Tratamiento de los tumores de células germinativas del ovario (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores de células germinativas del ovario.	células cancerosas destruyéndolas 0.567328 siguientes procedimientos 0.5945 estadio iv 0.763261 ovarios causa efectos 0.720865 siguientes tipos 0.44103 rayos x 0.435181 estadio ic 0.701359 estadio ib 0.706097 estadio ia 0.703099 enlace drugs approved 0.444726 Fallopian Tube 0.427273 células reproductoras 0.578706 área anormal.ampliar examen 0.456393 peritoneal primario 0.43365 estadio iva 0.49879 National Cancer Institute 0.427112 Instituto Nacional 0.496637 estadio iiia 0.688436 PDQ Tratamiento 0.459552	ligera presión 0.438027 estadio iiic 0.681996 ganglios linfáticos detrás 0.589451 estadio iia 0.703376 células madres 0.693148 cortará pequeños trozos 0.469591 presente sección 0.423353 estadio iic 0.591971 Physician Data Query 0.497349 or primary peritoneal 0.449903 estadio iii 0.989912 Nuevas opciones 0.42339 siguientes situaciones 0.508188 histerectomía abdominal 0.832509 siguientes pruebas 0.525524 siguientes sumarios 0.47228 corto tiempo 0.424715 siguientes estadios 0.515179	CLICK HERE
3427	National Cancer Institute	Html	es	Terapia láser para el tratamiento del cáncer	Hoja informativa que describe el uso de una luz de alta intensidad en el tratamiento del cáncer, sus ventajas y desventajas, y los tipos de procedimientos que la utilizan.	usa calor 0.497681 luz solar 0.504529 terapia láser usa 0.846675 usa rayos 0.615014 sustancia fotosensibilizadora 0.467924	alta intensidad 0.607112 terapia láser causa 0.851667 áreas minúsculas 0.473045 determinados síntomas 0.470796	CLICK HERE
16146	National Cancer Institute	Html	es	Virus de la enfermedad de Newcastle (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del virus de la enfermedad de Newcastle (VEN) como tratamiento para las personas con cáncer.	tumor cell immunogenicity 0.407212 Cancer Res Clin 0.40874 active specific immunotherapy 0.409234 abstract from 0.408151 with newcastle 0.446575 with virus-modified 0.40752 oncolytic virus 0.412098 Reichard KW 0.412175 with virally modified 0.408993 treated postsurgically with 0.409032 Cancer Res 0.456074 Schirrmacher V 0.472403 Csatary LK 0.410713 virus selectively kills 0.408217 Natl Cancer Inst 0.453624 human tumor 0.419154 immunotherapy with 0.411294 Attenuated veterinary virus 0.408258 Ahlert T 0.417009 patients with 0.422834 autologous tumor cells 0.443634 immunotherapy with virally 0.409777 immunization with 0.407432 Lorence RM 0.416992 modified autologous tumor 0.409356	newcastle disease virus 0.990705 virus infeccioso destrucción 0.419778 Lítica Virus 0.418733 virus as 0.414895 tumor cell modification 0.407198 tumor cells 0.594311 virus therapy 0.428512 specific immunotherapy 0.411581 postsurgically with newcastle 0.414603 Cassel WA 0.412481 tumor vaccines 0.414853 Clin Oncol 0.407495 patient with 0.407334 virus mutant with 0.411813 after local newcastle 0.411338 postoperative immunotherapy with 0.409993 malignant melanoma patients 0.409365 with tumor cells 0.411774 renal cell carcinoma 0.40842 malignant melanoma 0.414222 tumor necrosis 0.410434 in vitro 0.430542 virus is reviving 0.408425 active specific 0.412889	CLICK HERE
16653	National Cancer Institute	Html	en	IOTF Mentors: Track 3 and Track 4	While at FDA, fellows are assigned a mentor who is a senior member of FDA scientific review staff. Learn more about mentors for Tracks 3 and 4.	regulatory review 0.859055 Radiological Health 0.80074 review process 0.801152 project 0.796601 radiation therapy devices 0.823079 office 0.805677 Biologics Evaluation 0.882543 research 0.878646 therapy medical products 0.786754 medical products 0.814349 division 0.805276 cell-based medical products 0.805668 Biotechnology Products 0.814932 research program 0.805393 cell culture cells 0.78633 gene therapy products 0.878795 stem cells 0.79941 development 0.787013 cancer risk assessment 0.792173 gene therapy 0.961714 nucleic acid 0.824416 investigational new drug 0.905511 drug applications 0.79082 new drug products 0.789184	neoplastic cell substrates 0.79142 radiation therapy 0.854476 cancer chemotherapy 0.787392 radiation therapy treatments 0.789697 FDA 0.8111 Drug Evaluation 0.832004 Drug Administration 0.845645 cell 0.852835 therapeutic proteins 0.875837 cell therapy 0.796306 regulatory review scientist 0.807408 iotf fellow 0.867768 Principal Investigator 0.803321 Center 0.786741 early cancer detection 0.787952 Cancer Health Claims 0.787284 gene therapies 0.879766 cells 0.826854 immune cell activation 0.789452 fellow 0.909256 gene therapy applications 0.81743 cancer risk 0.812916 new medical products 0.802617 cancer 0.939352	CLICK HERE
16864	National Cancer Institute	Html	es	Selected Vegetables y Sun's Soup (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de Selected Vegetables y Sun's Soup como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Frozen SV 0.301838 Sun’s Soup 0.622837 Selected Vegetables 0.989854 specific dietary supplement 0.365272 multi-institutional prospective study 0.301068 Wang LH 0.31046 Sun Farm 0.310084 Instituto Nacional 0.303518 peso corporal promedio 0.301106 IV non-small 0.334303 Estados Unidos 0.309279 tratamiento simultáneoc puntaje 0.301389 Sun’s Soup“ 0.302908 allium cepa l 0.300921 patients taking 0.307016 non-small cell lung 0.365258 Lentinus edodes 0.303332 Sun Farm Corporation 0.305751 frijol mungo 0.301357 alimentario selected vegetables 0.303781 patients with 0.301382 investigación clínica 0.301025 glycine max l 0.300858 Yeh HC 0.310747 herbal treatment 0.309558	crataegus oxyacantha l 0.300911 Trademark Office 0.305198 puntaje promedio 0.304049 allium bakeri regel 0.300852 estadio iv 0.311573 Sun's Soup 0.425399 Pilot study 0.310803 glycyrrhiza glabra l 0.300901 cáncer número 0.301303 frijoles mungo 0.303086 Nutr Cancer 0.335867 US Patent 0.318672 Ryznar V 0.306737 Farm Vegetable Soup 0.306615 Ostadal O 0.306698 accessed april 0.311866 porcentaje promedio 0.301352 allium fistulosum l 0.300943 Glycine max 0.301356 Freeze-dried SV 0.300819 sesamum indicum l 0.300901 pacientes sí 0.303642 phaseolus radiatus l 0.305677 República Checa 0.301327	CLICK HERE